Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...